All lobbying filings

DLA PIPER LLP (US)

Lobbying for NOVARTIS · Innovative medicines company.

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 18, 2025

Income

$40,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 3

Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 3

HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
S 832
EPIC Act of 2025
HR 1672
Maintaining Investments in New Innovation Act

Lobbying activity 5

Pharmacy

Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act.

Medical/Disease Research/Clinical Labs

Issues related to rare disease and treatment. Drug and pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.

Intellectual property protections and enforcement. Biopharmaceutical patent policy.

Taxation/Internal Revenue Code

Tax reform and tax policy.

Trade (domestic/foreign)

Tariffs.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.